Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Joyce

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
Psychiatry Research|September 5, 2015
Facial recognition deficits as a potential endophenotype in bipolar disorderEsther Vierck, Richard J Porter, Peter R Joyce
Journal of Affective Disorders|August 29, 2003
Relationships among measures of treatment outcome in depressed patientsRoger T Mulder, Peter R Joyce, Chris Frampton
The Australian and New Zealand Journal of Psychiatry|September 7, 2010
How to reduce alcohol-related problems in adolescents: what can parents do and what can the government do?J Douglas Sellman, Jennie L Connor, Peter R Joyce
Pharmacogenetics and Genomics|May 6, 2009
Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorderPatrick C McHugh, Peter R Joyce, Martin R Kennedy
Pharmacogenomics|June 9, 2012
Institutional profile: The Carney Centre for Pharmacogenomics: a New Zealand focus for personalized medicine researchMartin A Kennedy, Peter R Joyce, Evan J Begg
Journal of Psychopharmacology (Oxford, England)|April 12, 2003
The prolactin response to fenfluramine in depression: effects of melancholia and baseline cortisolRoger T Mulder, Richard J Porter, Peter R Joyce
Psychopharmacology|November 20, 2002
Baseline prolactin and L-tryptophan availability predict response to antidepressant treatment in major depressionRichard J Porter, Roger T Mulder, Peter R Joyce
Neuroscience Letters|June 2, 2009
Expression and association analyses of promoter variants of the neurogenic gene HES6, a candidate gene for mood disorder susceptibility and antidepressant responseDylan M Glubb, Peter R Joyce, Martin A Kennedy
The Journal of Clinical Psychiatry|April 29, 2003
The relationship of personality disorders to treatment outcome in depressed outpatientsRoger T Mulder, Peter R Joyce, Suzanne E Luty
The Australian and New Zealand Journal of Psychiatry|January 17, 2008
Role of epigenetics in mental disordersSelma Stuffrein-Roberts, Peter R Joyce, Martin A Kennedy
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
Psychiatry Research|September 5, 2015
Facial recognition deficits as a potential endophenotype in bipolar disorderEsther Vierck, Richard J Porter, Peter R Joyce
Journal of Affective Disorders|August 29, 2003
Relationships among measures of treatment outcome in depressed patientsRoger T Mulder, Peter R Joyce, Chris Frampton
The Australian and New Zealand Journal of Psychiatry|September 7, 2010
How to reduce alcohol-related problems in adolescents: what can parents do and what can the government do?J Douglas Sellman, Jennie L Connor, Peter R Joyce
Pharmacogenetics and Genomics|May 6, 2009
Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorderPatrick C McHugh, Peter R Joyce, Martin R Kennedy
Pharmacogenomics|June 9, 2012
Institutional profile: The Carney Centre for Pharmacogenomics: a New Zealand focus for personalized medicine researchMartin A Kennedy, Peter R Joyce, Evan J Begg
Journal of Psychopharmacology (Oxford, England)|April 12, 2003
The prolactin response to fenfluramine in depression: effects of melancholia and baseline cortisolRoger T Mulder, Richard J Porter, Peter R Joyce
Psychopharmacology|November 20, 2002
Baseline prolactin and L-tryptophan availability predict response to antidepressant treatment in major depressionRichard J Porter, Roger T Mulder, Peter R Joyce
Neuroscience Letters|June 2, 2009
Expression and association analyses of promoter variants of the neurogenic gene HES6, a candidate gene for mood disorder susceptibility and antidepressant responseDylan M Glubb, Peter R Joyce, Martin A Kennedy
The Journal of Clinical Psychiatry|April 29, 2003
The relationship of personality disorders to treatment outcome in depressed outpatientsRoger T Mulder, Peter R Joyce, Suzanne E Luty
The Australian and New Zealand Journal of Psychiatry|January 17, 2008
Role of epigenetics in mental disordersSelma Stuffrein-Roberts, Peter R Joyce, Martin A Kennedy
Pageof 13